Alchemy vs Chainalysis: employee equity compared
Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Alchemy and Chainalysis.
Alchemy
Blockchain developer platform providing node infrastructure, APIs, SDKs, and monitoring tools for building decentralised applications on Ethereum, Solana, Polygon, and 18 other chains.
IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
Crypto-adjacent with cycle sensitivity; ISO/NSO options; liquidity tracks market conditions
Chainalysis
Blockchain analytics platform that traces cryptocurrency flows to detect illicit activity, provide compliance tools, and support law enforcement investigations.
No near-term IPO expected. Secondary trades at a discount vs last round — exercise timing requires caution. Company likely 2028+ at earliest; patient equity required.
Crypto-adjacent with cycle sensitivity; ISO/NSO options; secondary discount vs primary — price discovery ongoing; liquidity tracks market conditions
Key differences for employees
Equity structure
Alchemy grants ISO/NSO with strike prices ranging from $20–$40 depending on your grant year. Chainalysis grants ISO/NSO with strike prices from $18–$30.
Secondary market signal
Alchemy has no recent verified secondary signal — only the primary round ($10.2B) is shown. Chainalysis has no recent verified secondary signal. A higher secondary premium typically signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.
Revenue and growth
Alchemy runs at $0.1B ARR, growing +30% YoY (solid). Chainalysis runs at $0.3B ARR, growing +20% YoY (solid). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.
Liquidity timeline
Alchemy: IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
Chainalysis: No near-term IPO expected. Secondary trades at a discount vs last round — exercise timing requires caution. Company likely 2028+ at earliest; patient equity required.
Calculate your specific grant
Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value using peer-multiple, secondary-market, time-decay, and sector-momentum methods.